Last reviewed · How we verify
vasopressin - standard initiation
Vasopressin, marketed by The Cleveland Clinic, is a well-established drug in the therapeutic landscape. A key strength lies in its composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | vasopressin - standard initiation |
|---|---|
| Also known as | vasopressin |
| Sponsor | The Cleveland Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Early Versus Late Adjunctive Vasopressin in Septic Shock (PHASE4)
- Hemodynamics and Extravascular Lung Water in Acute Lung Injury (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vasopressin - standard initiation CI brief — competitive landscape report
- vasopressin - standard initiation updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI